Skip to main content
SpringerLink
Log in

Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

In addition to clinical and biological factors, further valuable prognostic information in neuroblastoma (Schwannian stroma-poor) (NB) patients is provided by the histopathologic analysis and the application of the International Neuroblastoma Pathology Classification (INPC) system. The objective of this study was to assess the prognostic impact of the INPC classification in a series of NB (Schwannian stroma-poor) and its relation with other prognostic factors. One hundred eighty-two cases of NB were collected from the files of the Spanish Neuroblastoma Registry. Slides were reviewed, and NB cases were grouped into favorable and unfavorable categories according to INPC criteria, taking into account morphological features (mitosis–karyorrhexis index, histological subtype) and patient’s age at diagnosis. Other pathological [presence of calcifications, tissular components, and number of mitotic cells per 10 high-power field (HPF)], immunohistochemical (P-glycoprotein and Ki-67 protein expression) and genetic (MYCN amplification and chromosome 1p deletion) features were also studied. Statistical analyses of overall survival with Kaplan–Meier curves and a multivariate study using Cox regression were performed (40.3% of NBs were considered favorable and 59.7% unfavorable). Unfavorable NB showed a mean survival time of 57 months compared with 89 months in favorable cases. Advanced stage, more than ten mitoses per 10 HPF, Ki-67 expression in more than 30% of tumor cells, MYCN oncogene amplification and chromosome 1p deletion were observed more frequently in unfavorable NB. The Cox regression analysis demonstrated that clinical stage (International Neuroblastoma Staging System stage 4) and histological subtype (undifferentiated NB) were the most important factors that influence the overall survival (p<0.001). INPC classification results are major prognostic indicators in NB and should be considered in the therapeutic stratification of NB patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ambros IM, Hata H, Joshi VV, Roald B, Dehner LP, Tüchler H, Pötschger U, Shimada H (2002) Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer 94:1574–1583

    Article  PubMed  Google Scholar 

  2. Ambros PF, Ambros IM (2001) Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492–504

    Article  PubMed  CAS  Google Scholar 

  3. Beckwith JB, Martin RF (1968) Observations on the histopathology of neuroblastomas. J Pediatr Surg 3:106–110

    Article  PubMed  CAS  Google Scholar 

  4. Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schafer KL, Terpe HJ, Lampert F, Boecker W, Dockhorn-Dworniczak B (1998) Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. Br J Cancer 77:2223–2229

    PubMed  CAS  Google Scholar 

  5. Brodeur GM (1993) TRK-A expression in neuroblastomas: a new prognostic marker with biological and clinical significance (editorial). J Natl Cancer Inst 85:344–345

    Article  PubMed  CAS  Google Scholar 

  6. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castleberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneko M, Kemshead J, Lampert F, Lee R, Look AT, Pearson AD, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voute PA (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477

    PubMed  CAS  Google Scholar 

  7. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D’Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI, Haase G, Hartmann O, Hayes FA, Helson L, Kemshead J, Lampert F, Ninane J, Ohkawa H, Philip T, Pinkerton CR, Pritchard J, Sawada T, Siegel S, Smith EI, Tsuchida Y, Voute PA (1988) International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874–1881

    PubMed  CAS  Google Scholar 

  8. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121–1124

    Article  PubMed  CAS  Google Scholar 

  9. Brown DC, Gatter KC (1990) Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17:489–503

    Article  PubMed  CAS  Google Scholar 

  10. Caron H (1995) Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 24:215–221

    Article  PubMed  CAS  Google Scholar 

  11. Caron H, Van Sluis P, De Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voute PA, Versteeg R (1996) Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334:225–230

    Article  PubMed  CAS  Google Scholar 

  12. Castel V, Garcia-Miguel P, Melero C, Navajas A, Navarro S, Molina J, Badal MD, Ruiz-Jimenez JI (1995) The treatment of advanced neuroblastoma. Results of the Spanish Neuroblastoma Study Group (SNSG) studies. Eur J Cancer 31A:642–645

    Article  PubMed  CAS  Google Scholar 

  13. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V (1991) P-Glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325:1608–1614

    Article  PubMed  CAS  Google Scholar 

  14. Chatten J, Shimada H, Sather HN, Wong KY, Siegel SE, Hammond GD (1988) Prognostic value of histopathology in advanced neuroblastoma: a report from the Childrens Cancer Study Group. Hum Pathol 19:1187–1198

    Article  PubMed  CAS  Google Scholar 

  15. Christiansen H, Lampert F (1988) Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 57:121–126

    PubMed  CAS  Google Scholar 

  16. Christiansen H, Sahin K, Berthold F, Hero B, Terpe H-J, Lampert F (1995) Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer 31A:541–544

    Article  PubMed  CAS  Google Scholar 

  17. Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ (1980) Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer 46:1896–1901

    Article  PubMed  CAS  Google Scholar 

  18. Evans AE, Chatten J, D’Angio GJ, Gerson JM, Robinson J, Schnaufer L (1980) A review of 17 IV-S neuroblastoma patients at the children’s hospital of Philadelphia. Cancer 45:833–839

    Article  PubMed  CAS  Google Scholar 

  19. Evans AE, D’Angio GJ, Propert K, Anderson J, Hann HW (1987) Prognostic factors in neuroblastoma. Cancer 59:1853–1859

    Article  PubMed  CAS  Google Scholar 

  20. Fong CT, White PS, Peterson K, Sapienza C, Cavenee WK, Kern SE, Vogelstein B, Cantor AB, Look AT, Brodeur GM (1992) Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 52:1780–1785

    PubMed  CAS  Google Scholar 

  21. George RE, Variend S, Cullinane C, Cotterill SJ, McGuckin AG, Ellershaw C, Lunec J, Pearson AD (2001) Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. Med Pediatr Oncol 36:169–176

    Article  PubMed  CAS  Google Scholar 

  22. Giorno R (1984) A comparison of two immunoperoxidase staining methods based on the avidin–biotin interaction. Diagn Immunol 2:161–165

    PubMed  CAS  Google Scholar 

  23. Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H (2001) Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer 92:2699–2708

    Article  PubMed  CAS  Google Scholar 

  24. Graham D, Magee H, Kierce B, Ball R, Dervan P, O’Meara A (1995) Evaluation of Ki-67 reactivity in neuroblastoma using paraffin embedded tissue. Pathol Res Pract 191:87–91

    PubMed  CAS  Google Scholar 

  25. Grosfeld JL, Schatzlein M, Ballantine TV, Weetman RM, Baehner RL (1978) Metastatic neuroblastoma: factors influencing survival. J Pediatr Surg 13:59–65

    Article  PubMed  CAS  Google Scholar 

  26. Hachitanda Y, Hata J (1996) Stage IVS neuroblastoma: a clinical, histological, and biological analysis of 45 cases. Hum Pathol 27:1135–1138

    Article  PubMed  CAS  Google Scholar 

  27. Hayashi Y, Kanda N, Inaba T, Hanada R, Nagahara N, Muchi H, Yamamoto K (1989) Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 63:126–132

    Article  PubMed  CAS  Google Scholar 

  28. Hughes M, Marsden HB, Palmer MK (1974) Histologic patterns of neuroblastoma related to prognosis and clinical staging. Cancer 34:1706–1711

    Article  PubMed  CAS  Google Scholar 

  29. Jereb B, Bretsky SS, Vogel R, Helson L (1984) Age and prognosis in neuroblastoma. Review of 112 patients younger than 2 years. Am J Pediatr Hematol Oncol 6:233–243

    Article  PubMed  CAS  Google Scholar 

  30. Joshi VV (2000) Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (modification of Shimada classification). Pediatr Dev Pathol 3:184–199

    Article  PubMed  CAS  Google Scholar 

  31. Joshi VV, Cantor AB, Altshuler G, Larkin EW, Neill JS, Shuster JJ, Holbrook CT, Hayes FA, Castleberry RP (1992) Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. A clinicopathologic study of 213 cases from the Pediatric Oncology Group. Cancer 69:2183–2196

    Article  PubMed  CAS  Google Scholar 

  32. Joshi VV, Cantor AB, Altshuler G, Larkin EW, Neill JS, Shuster JJ, Holbrook CT, Hayes FA, Nitschke R, Duncan MH, Shochat SJ, Talbert J, Smith EI, Castleberry RP (1992) Age-linked prognostic categorization based on a new histological grading system of neuroblastomas. A clinicopathologic study of 211 cases from the Pediatric Oncology Group. Cancer 69:2197–2211

    Article  PubMed  CAS  Google Scholar 

  33. Joshi VV, Chatten J, Sather HN, Shimada H (1991) Evaluation of the Shimada classification in advanced neuroblastoma with a special reference to the mitosis–karyorrhexis index: a report from the Children’s Cancer Study Group. Mod Pathol 4:139–147

    PubMed  CAS  Google Scholar 

  34. Joshi VV, Rao PV, Cantor AB, Altshuler G, Shuster JJ, Castleberry RP (1996) Modified histologic grading of neuroblastomas by replacement of mitotic rate with mitosis karyorrhexis index. A clinicopathologic study of 223 cases from the Pediatric Oncology Group. Cancer 77:1582–1588

    Article  PubMed  CAS  Google Scholar 

  35. Kaneko Y, Kanda N, Maseki N, Sakurai M, Tsuchida Y, Takeda T, Okabe I, Sakurai M (1987) Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 47:311–318

    PubMed  CAS  Google Scholar 

  36. Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP, Cohn SL (1998) Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D (S) neuroblastoma: the Pediatric Oncology Group experience—a Pediatric Oncology Group study. J Clin Oncol 16:2007–2017

    PubMed  CAS  Google Scholar 

  37. Kobayashi C, Monforte-Munoz HL, Gerbing RB, Stram DO, Matthay KK, Lukens JN, Seeger RC, Shimada H (2005) Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis–karyorrhexis index. Cancer 103:174–180

    Article  PubMed  Google Scholar 

  38. Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O’Neill S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, Pearson AD, Jackson MS (2001) Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19:3080–3090

    PubMed  CAS  Google Scholar 

  39. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA (1984) Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231–235

    Article  PubMed  CAS  Google Scholar 

  40. Makinen J (1972) Microscopic patterns as a guide to prognosis of neuroblastoma in childhood. Cancer 29:1637–1646

    Article  PubMed  CAS  Google Scholar 

  41. Navarro S, Amann G, Beiske K, Cullinane CJ, d’Amore E, Gambini C, Mosseri V, De Bernardi B, Michon J, Peuchmaur M (2006) Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of Localized Neuroblastoma European Study Group 94.01 Trial and Protocol. J Clin Oncol 24:695–699

    Article  PubMed  Google Scholar 

  42. Poremba C, Scheel C, Hero B, Christiansen H, Schaefer KL, Nakayama J, Berthold F, Juergens H, Boecker W, Dockhorn-Dworniczak B (2000) Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 18:2582–2592

    PubMed  CAS  Google Scholar 

  43. Poremba C, Willenbring H, Hero B, Christiansen H, Schafer KL, Brinkschmidt C, Jurgens H, Bocker W, Dockhorn-Dworniczak B (1999) Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. Ann Oncol 10:715–721

    Article  PubMed  CAS  Google Scholar 

  44. Rudolph P, Lappe T, Hero B, Berthold F, Parwaresch R, Harms D, Schmidt D (1997) Prognostic significance of the proliferative activity in neuroblastoma. Am J Pathol 150:133–145

    PubMed  CAS  Google Scholar 

  45. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111–1116

    Article  PubMed  CAS  Google Scholar 

  46. Shimada H (1992) Neuroblastoma. Pathology and biology. Acta Pathol Jpn 42:229–241

    PubMed  CAS  Google Scholar 

  47. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B (1999) Terminology and morphologic criteria of neuroblastic tumors. Recommendations by the International Neuroblastoma Pathology Committee. Cancer 86:349–363

    Article  PubMed  CAS  Google Scholar 

  48. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lokens JN, Matthay KK, Castleberry RP (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364–372

    Article  PubMed  CAS  Google Scholar 

  49. Shimada H, Chatten J, Newton WA, Sachs N, Hamoudi AB, Chiba T, Marsden HB, Misugi K (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405–416

    PubMed  CAS  Google Scholar 

  50. Shimada H, Stram D, Chatten J, Joshi VV, Hachitanda Y, Brodeur G, Lukens J, Matthay K, Seeger R (1995) Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 87:1470–1476

    Article  PubMed  CAS  Google Scholar 

  51. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawara A, Goto S, Gerbing RB, Stram D, Lukens JN, Matthay KK (2001) International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer 92:2451–2461

    Article  PubMed  CAS  Google Scholar 

  52. Tsuda T, Obara M, Hirano H, Gotoh S, Kubomura S, Higashi K, Kuroiwa A, Kakagawara A, Nagahara N, Shimizu K (1987) Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas. Cancer 60:820–826

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

Supported by grant no. G03/089 from Instituto Carlos III, Madrid, Spain.

Author information

Authors and Affiliations

  1. Departamento de Patología, Facultad de Medicina de Valencia, Avda. Blasco Ibañez, 17, E-46010, Valencia, Spain

    Octavio Burgues, Samuel Navarro, Rosa Noguera, Antonio Pellín, Amparo Ruiz & Antonio Llombart-Bosch

  2. Pediatric Oncology Unit, Hospital Universitario “La Fe”, Valencia, Spain

    Victoria Castel

Authors
  1. Octavio Burgues
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosa Noguera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Pellín
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amparo Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Victoria Castel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio Llombart-Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel Navarro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burgues, O., Navarro, S., Noguera, R. et al. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch 449, 410–420 (2006). https://doi.org/10.1007/s00428-006-0253-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-006-0253-y

Keywords

Search

Navigation